Vision loss associated with silicone oil endotamponade in vitreoretinal surgery - a review.

Autor: Januschowski K; Mount St. Peter Eye Clinic, Max-Planck-Str. 14-16, 54296, Trier, Germany.; Medical Department, University of Tuebingen, Tuebingen, Germany., Rickmann A; Medical Department, University of Tuebingen, Tuebingen, Germany. annekatrin.rickmanni@kksaar.de.; Ophthalmology Department, Knappschaft Hospital Sulzbach, Sulzbach/Saar, Germany. annekatrin.rickmanni@kksaar.de., Smith J; Sunderland Eye Infirmary, Queen Alexandra Road, Sunderland, SR2 9HP, UK., Pastor-Idoate S; Institute of Applied Ophthalmobiology (IOBA), University of Valladolid, Valladolid, Spain.; Ophthalmology Department, Hospital Clinico Universitario, Valladolid, Spain., Pastor JC; Institute of Applied Ophthalmobiology (IOBA), University of Valladolid, Valladolid, Spain.
Jazyk: angličtina
Zdroj: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie [Graefes Arch Clin Exp Ophthalmol] 2024 Nov; Vol. 262 (11), pp. 3453-3463. Date of Electronic Publication: 2024 Jun 18.
DOI: 10.1007/s00417-024-06520-y
Abstrakt: Purpose: To clarify the definition, prevalence and classification of different types of unexplained vision loss associated with silicone oil (SO) endotamponades (SO in situ (SOIS) or after removal of SO (ROSO)) in vitreoretinal surgery and identifying the most specific clinical findings and suggesting possible causes.
Methods: Review of the literature regarding randomized clinical trials (RCTs), retrospective case-control, cohort studies and case series evaluating the risk of using SO, published in English between 1994 and 2023, conducting a computer-based search of the following databases: PubMed, Web of Science, Scopus and Embase. The search was supplemented using the Medline option 'Related Articles' and consulting review articles on the topic.
Results: Findings from reported clinical examinations in SOIS and ROSO are analyzed and finally different theories regarding the underlying pathophysiology are described. From the clinical point of view, findings have been found in OCT, OCTA, microperimetry and electrophysiological studies. Other clearly identifiable causes of vision loss related to the use of SO are listed and commented as differential diagnosis. Finally, the different physiopathological theories of the two types of causes of unexplained vision have been analyzed.
Conclusion: Unexpected vision loss under or after SO tamponade (SOIS and ROSO) is a significant concern which is probably underestimated because it is not a clearly defined and known entity. The most frequently described changes were in the ganglion cell complex but this unexpected vision loss remains a serious and unexplained concern for vitreoretinal surgeons and should be identified by clinicians, addressed by manufacturers and reported to Health Authorities as a serious incident according to the new regulation.
Competing Interests: Declarations. Conflicts of interest: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. Research involving human participants and/or animals: This review did not involve human participants. Informed consent: This review did not involve human participants.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: